Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (åpner nytt vindu)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Kilde‎: Hemoglobin 2014;38(1):44-8.

Arkiv‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (åpner nytt vindu)

Hydroxyurea in thalassemia intermedia--a promising therapy. (åpner nytt vindu)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Kilde‎: Ann Hematol 2005;84(7):441-6.

Arkiv‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (åpner nytt vindu)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (åpner nytt vindu)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Kilde‎: J Clin Pathol 2010;63(2):147-50.

Arkiv‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (åpner nytt vindu)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (åpner nytt vindu)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Kilde‎: Eur J Haematol 2009;82(3):213-8.

Arkiv‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (åpner nytt vindu)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (åpner nytt vindu)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Kilde‎: Eur J Haematol 2010;84(1):52-8.

Arkiv‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (åpner nytt vindu)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (åpner nytt vindu)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Kilde‎: Blood Cells Mol Dis 2000;26(5):453-66.

Arkiv‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (åpner nytt vindu)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (åpner nytt vindu)

Perrine SP.

Kilde‎: Pediatr Ann 2008;37(5):339-46.

Arkiv‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (åpner nytt vindu)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (åpner nytt vindu)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Kilde‎: Ann N Y Acad Sci 2005;1054:250-6.

Arkiv‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (åpner nytt vindu)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (åpner nytt vindu)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Kilde‎: Acta Haematol 2004;111(4):189-95.

Arkiv‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (åpner nytt vindu)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (åpner nytt vindu)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Kilde‎: Blood Purif 2004;22(5):453-60.

Arkiv‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (åpner nytt vindu)

The role of recombinant human erythropoietin in the treatment of thalassemia. (åpner nytt vindu)

Rachmilewitz EA, Aker M.

Kilde‎: Ann N Y Acad Sci 1998;850:129-38.

Arkiv‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (åpner nytt vindu)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (åpner nytt vindu)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Kilde‎: Br J Haematol 2011;154(2):281-4.

Arkiv‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (åpner nytt vindu)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (åpner nytt vindu)

Thein SL.

Kilde‎: Blood Rev 2012;26 Suppl 1:S35-9.

Arkiv‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (åpner nytt vindu)